

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

Print selected from Online session21/11/2002

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:30:47 ON 21 NOV 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:31:00 ON 21 NOV 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 NOV 2002 HIGHEST RN 474043-36-2

DICTIONARY FILE UPDATES: 20 NOV 2002 HIGHEST RN 474043-36-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10066503.str


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Print selected from Online session13:33Page 2



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> sl1
SL1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s l1
SAMPLE SEARCH INITIATED 13:31:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 498 TO ITERATE
```

```
100.0% PROCESSED      498 ITERATIONS                      8 ANSWERS
SEARCH TIME: 00.00.03
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   8622 TO 11298
PROJECTED ANSWERS:      8 TO 329
```

```
L2          8 SEA SSS SAM L1
```

```
=> s l1 ful
FULL SEARCH INITIATED 13:31:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10264 TO ITERATE
```

```
100.0% PROCESSED    10264 ITERATIONS                      106 ANSWERS
SEARCH TIME: 00.00.05
```

```
L3          106 SEA SSS FUL L1
```

```
=> file uspatall
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                140.28      140.49
```

```
FILE 'USPATFULL' ENTERED AT 13:31:37 ON 21 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'USPAT2' ENTERED AT 13:31:37 ON 21 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
=> sl3
SL3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s l3
L4          2 L3
```

```
=> d a bs bib hitstr 1-2
'A' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
'BS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
```

The following are valid formats:

The default display format is STD.

```
ABS ----- AB
ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
            RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
            DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
            INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
            EXF, ARTU
ALLG ----- ALL plus PAGE.DRAW
BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
            PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ----- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must
               entered on the same line as DISPLAY, e.g., D BROWSE.
CAS ----- OS, CC, SX, ST, IT
CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ----- ALL, delimited for post-processing
FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
            PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
            NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
            CLMN, DRWN, AB
FP.EX ----- FP for original and latest publication
FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
            RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
            NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
            PARN, SUMM, DRWD, DETD, CLM
FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
            RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ----- HIT RN, its text modification, its CA index name, and
               its structure diagram
FPG ----- FP plus PAGE.DRAW
GI ----- PN and page image numbers
HIT ----- All fields containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
               its structure diagram
IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IALLG ----- IALL plus PAGE.DRAW
IBIB ----- BIB, indented with text labels
IBIB.EX ----- IBIB for original and latest publication
IBIBG ----- IBIB plus PAGE.DRAW
```

Print selected from Online session21/11/2002

IMAX ----- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU, OS, CC, SX, ST, IT
ISTD ----- STD, indented with text labels
KWIC ----- All hit terms plus 20 words on either side
MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC ----- List of display fields containing hit terms
SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
DT, FS, LN.CNT
SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
without answer number. SCAN must be entered on the
same line as DISPLAY, e.g., D SCAN)
STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d abs bib hitstr 1-2

L4 ANSWER 1 OF 2 USPATFULL

AB Compounds useful as inhibitors of PDE4 in the treatment of diseases
regulated by the activation and degranulation of eosinophils, especially
asthma, chronic bronchitis, and chronic obstructive pulmonary disease,
of the formula: ##STR1##

wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is
selected from the partial Formulas: ##STR2##

where q is 1, 2, or 3, W.sup.3 is --O--; --N(R.sup.9)--; or
--OC(.dbd.O)--; R.sup.7 is selected from --H; --(C.sub.1-C.sub.6) alkyl,
--(C.sub.2-C.sub.6) alkenyl, or --(C.sub.2-C.sub.6) alkynyl substituted
by 0 to 3 substituents R.sup.10; --(CH.sub.2).sub.u--(C.sub.3-C.sub.7)
cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R.sup.10; and
phenyl or benzyl substituted by 0 to 3 R.sup.14; R.sup.8 is
tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl;
1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-
yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl;
1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-
yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl;
oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl;
succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl;
4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl;
pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl;
2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl;
2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl;
benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl;
benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl;
isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl;
pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl;

Print selected from Online session13:33Page 5

pteridinylyl; or 1H-purinylyl; or A is selected from phosphorous and sulfur acid groups; W is --O--; --S(.dbd.O).sub.t--; where t is 0, 1, or 2; or --N(R.sup.3)--; Y is .dbd.C(R.sup.1.sub.a)--; or --[N(O).sub.k] where k is 0 or 1; R.sup.4, R.sup.5 and R.sup.6 are (1) --H; provided that R.sup.5 and R.sup.6 are not both --H at the same time, --F; --Cl; --(C.sub.2-C.sub.4) alkynyl; --R.sup.16; --OR.sup.16; --S(.dbd.O).sub.pR.sup.16; --C(.dbd.O)R.sup.16, --C(.dbd.O)OR.sup.16, --C(.dbd.O)OR.sup.16; --OC(.dbd.O)R.sup.16; --CN; --NO.sub.2; --C(.dbd.O)NR.sup.16R.sup.17; --OC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NR.sup.12)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NCN)NR.sup.16R.sup.16; --NR.sup.12.sub.aC(.dbd.N--NO.sub.2)NR.sup.15R.sup.16; --C(.dbd.NR.sup.12.sub.a)NR.sup.15R.sup.16; --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.N--NO.sub.2)NR.sup.16R.sup.17; --NR.sup.16R.sup.17; --CH.sub.2NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)R.sup.16; --NR.sup.12.sub.aC(.dbd.O)OR.sup.16; .dbd.NOR.sup.16; --NR.sup.12.sub.aS(.dbd.O).sub.pR.sup.17 --S(.dbd.O).sub.pNR.sup.16R.sup.17; and --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; (2) --(C.sub.1-C.sub.4) alkyl including dimethyl and --(C.sub.1-C.sub.4) alkoxy substituted with 0 to 3 substituents --F or --Cl; or 0 or 1 substituent (C.sub.1-C.sub.2) alkoxycarbonyl-, (C.sub.1-C.sub.2) alkylcarbonyl-, or (C.sub.1-C.sub.2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R.sup.5 and R.sup.6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): ##STR3##


or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:206794 USPATFULL
 TI Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
 IN Magee, Thomas Victor, Mystic, CT, UNITED STATES
 Marfat, Anthony, Mystic, CT, UNITED STATES
 Chambers, Robert James, Mystic, CT, UNITED STATES
 PA Pfizer Inc. (U.S. corporation)
 PI US 2002111495 A1 20020815
 AI US 2002-62811 A1 20020131 (10)
 PRAI US 2001-265240P 20010131 (60)
 US 1997-43403P 19970404 (60)
 US 1998-105120P 19981021 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
 CLMN Number of Claims: 22
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 7710


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 214754-96-8P 214754-98-0P 214755-00-7P
 (prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)
 RN 214754-96-8 USPATFULL
 CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 214754-98-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 214755-00-7 USPATFULL

CN 3-Pyridinecarboxamide, N-[[4-methoxyphenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 USPATFULL

AB A compound of formula (I) wherein m, n, o, p, q, r, A, B, D, E, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the description, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AN 2002:95811 USPATFULL
TI Nicotinamide derivatives
IN Marfat, Anthony, Mystic, CT, United States
Chambers, Robert J., Mystic, CT, United States
Watson, John W., Ledyard, CT, United States
Cheng, John B., Waterford, CT, United States
Duplantier, Allen J., Ledyard, CT, United States
Kleinman, Edward F., Pawcatuck, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6380218 B1 20020430
WO 9845268 19981015
AI US 1999-308956 19990527 (9)
WO 1998-IB315 19980310
19990527 PCT 371 date
PRAI US 1997-43403P 19970404 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Richardson, Peter C., Ginsburg, Paul H., Speer, Raymond M.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 214754-96-8P 214754-98-0P 214755-00-7P
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)


RN 214754-96-8 USPATFULL


CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 214754-98-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)





RN 214755-00-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(3-pyridinyloxy)-
(9CI) (CA INDEX NAME)



=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
17.69	158.18

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:32:58 ON 21 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Nov 2002 VOL 137 ISS 21
FILE LAST UPDATED: 20 Nov 2002 (20021120/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please


L5 4 L3

I.5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

GI



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F, Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd.

as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

AN 2002:594842 CAPLUS

DN 137:154859

TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes

IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 285 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060896	A1	20020808	WO 2001-IB2726	20011224
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2001-265304P	P	20010131		
OS	MARPAT 137:154859				
IT	445294-90-6P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(PDE4 isoenzyme inhibitor; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)				
RN	445294-90-6	CAPLUS			
CN	3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-oxoethoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d abs bib fhitr 2-4

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

AN 2002:591707 CAPLUS

DN 137:140509

TI Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes

IN Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony

PA Pfizer Products Inc., USA


SO Eur. Pat. Appl., 180 pp.

CODEN: EPXXDW

DT Patent
LA English


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1229034	A1	20020807	EP 2002-250202	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002111495	A1	20020815	US 2002-62811	20020131
	BR 2002000250	A	20021008	BR 2002-250	20020131
PRAI	US 2001-265240P	P	20010131		
	US 1997-43403P	P	19970404		
	US 1998-105120P	P	19981021		
OS	MARPAT 137:140509				
IT	444807-21-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(claimed compd.; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)				
RN	444807-21-0	CAPLUS			
CN	Benzeneacetic acid, 4-[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-methoxy-.alpha.,.alpha.-dimethyl- (9CI)				
	(CA INDEX NAME)				



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
GI



AB Title compds. [I; wherein m is 0 or 1; n is 0 or 1; o is 0-4; p is 0 or 1; q is 0 or 1; r is 0-4; t is 0 or 1; A is oxygen, NH, or sulfur; B is oxygen or NH; D is oxygen, NH, or alkylamino; E is CH₂, O, NH, SO, SO₂, S; R₁ is H, alkyl, cycloalkyl, aryl, etc.; R₂, R₃ together with attached carbon form carbonyl group or cycloalkyl ring; R₂, R₃, R₄ is independently H, OH, CN, CO₂H, alkyl, etc.; R₅ is cyclic, bicyclic, aryl; R₆, R₇ and R₈ are each independently H, CN, COOH, NO₂, OH, alkyl, etc.] and pharmaceutical compn. are prepd. for the treatment of respiratory, allergic, rheumatoid, body wt. regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, wt. control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

AN 1998:682365 CAPLUS

DN 129:316147

TI Preparation of nicotinamides as PDE4' D isoenzymes inhibitors

IN Marfat, Anthony; Chambers, Robert James; Watson, John Wesley; Cheng, John Bin; Duplantier, Allen Jacob; Kleinman, Edward Fox

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 200 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9845268	A1	19981015	WO 1998-IB315	19980310
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9862273	A1	19981030	AU 1998-62273	19980310
	AU 738037	B2	20010906		
	EP 971894	A1	20000119	EP 1998-904343	19980310
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2000510481	T2	20000815	JP 1998-542528	19980310
	BR 9810733	A	20000912	BR 1998-10733	19980310
	ZA 9802853	A	19991004	ZA 1998-2853	19980403
	US 6380218	B1	20020430	US 1999-308956	19990527
	NO 9904791	A	19991201	NO 1999-4791	19991001

US 2002111495 A1 20020815 US 2002-62811 20020131
 PRAI US 1997-43403P P 19970404
 WO 1998-IB315 W 19980310
 US 1998-105120P P 19981021
 US 2001-265240P P 20010131
 OS MARPAT 129:316147
 IT 214754-96-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)
 RN 214754-96-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
 GI



AB The title compds. [I; R1 = alkyl; R2 = (halo)alkyl; R3 = H, halo; R4-R6 = H, C1-6 alkyl, C1-4 haloalkyl, etc.; R7, R8 = H, (substituted) alkyl, Ph, R7R8N = 3-9-membered heterocycle] are prepd. and formulated. Pyrazole deriv. II (1.3 g) was stirred with KOH in MeOH at room temp., MeOH was distd., toluene was added and distd., the remaining solid was heated with 1.0 g chloropyridine deriv. III and 0.01 g CuCl in DMF at 110.degree. to

give 0.80 g I (R1 = Me, R2 = 3-CF3, R3-R7 = H, R8 = 6-CH2CF3), which controlled >90% barnyard grass, *Setaria viridis*, etc. at 2.5 kg/ha.

AN 1996:132822 CAPLUS
 DN 124:176091
 TI Preparation of (pyridyloxy)pyrazole derivatives as herbicides
 IN Morimoto, Katsuyuki; Oonari, Masatoshi; Furusawa, Hiroyuki; Hatanaka, Masataka; Watanabe, Junichi; Kondo, Yasuo; Nawamaki, Tsutomu; Ishikawa, Kimihiro; Shiojima, Kenichi; Nakahira, Kunimitsu
 PA Nissan Chemical Ind Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 30 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07285962	A2	19951031	JP 1994-81585	19940420
OS	MARPAT 124:176091				
IT	173946-99-1P				

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of (pyridyloxy)pyrazole derivs. as herbicides)

RN 173946-99-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

